On July 18 and 19, over 150 professionals gathered in Rockville, MD and virtually to identify and address the barriers to adoption of pharmaceutical continuous manufacturing (PCM). Informative presentations and discussions led by FDA, industry, academia, USP, and other key stakeholders, provided actionable insights, strategies, and potential solutions for attendees. Review the links below to gain more insight about these presentations and we will continue to share updates on this thread.
Katie Baumer @ on
On July 18 and 19, over 150 professionals gathered in Rockville, MD and virtually to identify and address the barriers to adoption of pharmaceutical continuous manufacturing (PCM). Informative presentations and discussions led by FDA, industry, academia, USP, and other key stakeholders, provided actionable insights, strategies, and potential solutions for attendees. Review the links below to gain more insight about these presentations and we will continue to share updates on this thread.
To kick off this conversation, we’d like to hear from you – what are the biggest barriers to adoption of CM in your organization? Share your thoughts!